Last updated: June 14, 2026
Spironolactone and Hydrochlorothiazide Suppliers: API, Finished Dose, and Contract Manufacturing Landscape (US & Key Markets)
Suppliers split into two buckets: (1) active pharmaceutical ingredient (API) producers for spironolactone and hydrochlorothiazide and (2) finished-dose manufacturers and contract development and manufacturing organizations (CDMOs) that can supply combination tablets (spironolactone + hydrochlorothiazide). The combination is common in the US, EU, and many ROW markets, but supplier counts narrow further when you factor in inspection history, DMF/CEP status, and capability for combination tablets.
What companies supply spironolactone and hydrochlorothiazide APIs (and where are they based)?
Typical spironolactone API supply comes from specialty generics and steroid API manufacturers, with additional capacity from China and India. Hydrochlorothiazide API supply is broader because the molecule is mature and widely produced at scale.
Spironolactone API supplier profile
Common supplier archetypes:
- Steroid and hormone-focused API manufacturers (scale for low- to mid-volume APIs).
- General generics API producers with controlled substance-free manufacturing lines and established FDA/EMA filing packages.
- Contract API makers for intermediates and final API with custom polymorph and particle-size control.
Hydrochlorothiazide API supplier profile
Common supplier archetypes:
- High-throughput small-molecule API producers.
- Broad generics API suppliers with multiple grades and packaging formats (granular, micronized) for tableting.
- Manufacturers with established DMFs/DMF-lite packages and routine regulatory support for US and EU filings.
How to map “supplier” for tendering
For drug product procurement or licensing diligence, treat “supplier” as one of:
- API manufacturer (API supply agreement + regulatory filing ownership or authorization)
- Finished-dose manufacturer (ANDA/NDA or RLD supplier chain)
- CDMO for combination tablets (formulation + blending + coating + packaging)
- Distributor (adds lead time and inventory risk, but can bridge multiple API sources)
Who manufactures spironolactone and hydrochlorothiazide combination tablets (finished dose suppliers)?
Combination tablets are typically sourced through:
- US generic manufacturers with established 505(b)(2) or ANDA portfolios for combination products
- ROW branded suppliers under license, then distributed domestically
- CDMOs that produce the commercial tablet line under label ownership
Key finished-dose supplier types
- Large US generic manufacturers with combination diuretic portfolios
- Regional ROW players with registered combination strengths
- CDMOs producing under contract where the brand holder owns the approval and label
Why finished-dose suppliers differ from API suppliers
Even if the API supply is shared across multiple brands, tablet manufacturing can be constrained by:
- granulation and compression process capability for each strength
- impurity control and stability (especially for spironolactone)
- blister or bottle packaging line compatibility
- validated cleaning and hold-time controls for batch-to-batch consistency
Which APIs and excipients drive supplier qualification risk for the combination?
Supplier qualification is usually dominated by:
- API impurity profile and batch consistency
- polymorphic form and particle-size distribution (affects dissolution for thiazides and tablet uniformity)
- moisture sensitivity and storage stability for spironolactone-containing blends
- excipient sourcing for consistent tablet hardness, disintegration, and coating adhesion
Typical qualification checkpoints
- DMF/ASMF alignment to the selected API supplier and manufacturing site
- CoA and release testing trend (assay, impurities, water content, particle-size)
- Stability data for the final tablet formulation
- GMP inspection record and remediation history for the specific site
What supplier documentation is required for regulatory filings (DMF, CEP, ASMF, and site authorization)?
For combination tablets, the regulatory chain often requires:
- DMF (US) authorization for the selected API site(s)
- ASMF/CEP alignment for EU market strategies
- Cross-reference letters when API is supplied from a different site than the initially filed one
US pathway framing
A typical generic combination submission relies on:
- established reference product basis (if applicable)
- API control strategy tied to the DMF
- method and impurity specs matching the clinical and bioequivalence narrative
EU pathway framing
EU files often require:
- ASMF updates tied to site changes
- CEP if used as a compliance lever
- GMP certificates for API and tablet sites
When do generic or combination tablet suppliers enter, and what supply gaps appear around exclusivity?
The combination itself does not create unique regulatory exclusivity in all cases because many strengths exist as mature products. Supply timing is more driven by:
- ANDA/authorization launch windows
- site readiness (cleanroom, compression/blending lines)
- API long lead times during market spikes
Practical procurement timing
- API lead-time planning is the biggest swing factor.
- Tablet manufacturing scheduling follows regulatory release plus packaging availability.
- Inventory strategy often determines whether procurement stays on contract or shifts to spot buys.
What patent estate and litigation affect suppliers and generic entry for spironolactone plus hydrochlorothiazide?
Patent constraints rarely block API supply but can block product launches by specific dosage forms, formulations, or specific method-of-use claims. For procurement and supplier diligence, focus on:
- Orange Book listing status of specific strengths and dosage forms
- any Paragraph IV litigation that could affect availability and distribution timelines
- formulation patenting (coating, granulation method, or stability-enhancing approaches)
How this affects supplier risk
- A supplier may still provide API, but the finished-dose launch may be delayed or redesigned.
- In some cases, the combination tablet is supplied but distribution may be constrained by label approval status or exclusivity under the approval.
What is the supplier competitive landscape by geography (US, EU, India, China)?
US
- Finished-dose supply dominates through generic manufacturers and specialized diuretic portfolios.
- API supply in US filings typically uses approved DMF sites even when API is imported.
EU
- Combination products are supplied through national and EU-wide registered generics.
- API supply requires ASMF/CEP alignment and validated import processes.
India and China
- Both countries dominate API production volume for mature molecules like hydrochlorothiazide.
- Spironolactone capacity is present but can be more selective by regulatory site status and inspection history.
How strong is the manufacturing/IP barrier for combination tablets (CDMO and formulation constraints)?
For spironolactone + hydrochlorothiazide tablets, manufacturing barriers are usually practical, not IP-driven:
- process robustness for blending and compressing two actives with different particle and flow characteristics
- impurity control and stability under typical storage conditions
- cross-contamination controls and line clearance validation
CDMO decision factors
- experience with diuretics and steroid APIs
- validated analytical methods for content uniformity and impurities
- blister/bottle packaging line qualification
- ability to support tech transfer quickly and reproducibly
What contract manufacturing models do suppliers use for combination products?
Common models:
- Label owner + CDMO manufacturing with outsourced packaging
- API supplied under long-term supply plus intermediate management
- “Bottle-fill only” or “labeler-only” structures in distribution-heavy environments
Procurement implications
- If the API is constrained, the CDMO’s bottle/blister capacity does not solve supply.
- If the tablet line is constrained, API stock can sit idle until manufacturing scheduling catches up.
Supplier due-diligence checklist for spironolactone and hydrochlorothiazide
Use this for vendor qualification and audit planning:
- Manufacturing site GMP compliance status (API and drug product sites)
- Filed and authorized DMF/ASMF access for the intended market(s)
- Evidence of impurity controls and CoA trend for last 6 to 12 months
- Stability support for the exact tablet strength and packaging configuration
- Capacity confirmation for the specific manufacturing period and packaging format
- Ability to support change control: scale-up, blending parameters, and supplier site changes
- Supply chain continuity plan for API grade and excipient substitutions
Key Takeaways
- “Suppliers” for spironolactone + hydrochlorothiazide must be split into API sites and finished-dose/CDMO manufacturing sites; the qualification chain differs.
- Hydrochlorothiazide API has broader supply availability; spironolactone supply can be more constrained by site status and inspection outcomes.
- Combination tablet supply risk is typically driven by tablet manufacturing scheduling, excipient stability, and packaging availability, not API availability alone.
- Regulatory readiness hinges on DMF/ASMF authorization and site-specific control strategy that matches the intended approval.
FAQs
1) What is the difference between spironolactone + hydrochlorothiazide API suppliers and finished-dose tablet suppliers?
API suppliers provide the active substances; finished-dose suppliers provide the approved tablets and packaging with regulatory quality systems tied to the specific product approval.
2) Which part of the supply chain is most likely to cause shortages for the combination?
Tablet manufacturing capacity and packaging lead times are common bottlenecks, even when API is available.
3) How do DMF and ASMF filings affect which suppliers can be used?
You can generally only use API suppliers whose sites are covered by the required filings (or authorized cross-references) for the target market.
4) Do supplier changes trigger regulatory re-approval or supplements?
Often yes. Site or process changes require change control and may trigger regulatory supplements depending on the scale, risk, and filing requirements.
5) What should procurement prioritize when selecting a CDMO for the combination tablets?
Validated blending/compression capability for the two actives, stability support for the target strengths, packaging line readiness, and proven impurity control.
References
- FDA. “Drug Master Files (DMFs).” US Food and Drug Administration.
- EMA. “ASMF guidance and procedures.” European Medicines Agency.
- FDA. “ANDA approvals and regulatory pathways overview.” US Food and Drug Administration.
